Valerius Biopharma AG is a biopharmaceutical company that has been founded to provide interchangeable treatment options for high-priced biologics, by developing specialty biosimilars including but not limited to orphan drug biosimilars. Our interdisciplinary team of experts combines decades of experience gained in the biotechnology and biosimilar industry. Excellent process science, deep knowledge and understanding of proteins with their underlying complexity, as well as profound clinical and regulatory expertise, are key factors of our success. The product pipelines comprises four products currently in preclinical development stages and include monoclonal antibodies, enzymes and fusion proteins covering different therapeutic areas such as oncology, inflammation, ophthalmology and respiratory. The development of our future pipeline candidates is planned to commence in 2022. The company is driven by a team with proven track-records in biopharmaceutical / biosimilar development and finance.